超声声像变化评价乳腺癌新辅助化疗的疗效

Ultrasonographic changes evaluation of response to neoadjuvant chemotherapy in breast cancer

目的研究超声显像在乳腺癌新辅助化疗前后疗效评价的价值。方法以外科手术切除的乳腺癌组织病理学疗效评价为依据分组,对新辅助化疗前后乳腺癌超声显像行回顾性对比和分析。结果(1)新辅助化疗后乳腺癌瘤体多数缩小或消失。(2)组织病理学疗效评价:按照既往评价系统分,治疗反应轻度者19例,中度47例,重度12例。(3)新辅助化疗后超声显像变化:周边高回声晕显示率均增加,轻度(P<0.05)和中度(P<0.01)治疗反应组有统计学差异;边缘毛刺征显示率均减少,中度(P<0.01)治疗反应组有统计学差异;腋窝转移淋巴结显示减少,中度(P<0.01)和重度(P<0.05)治疗反应组有统计学差异;PDI检测血供明显减少,中度(P<0.01)和重度(P<0.05)治疗反应组有统计学差异。结论超声显像可成为手术前乳腺癌新辅助化疗疗效评估的实用性技术。

Objective To investigate the ultrasonographic changes of response to neoadjuvant chemotherapy in breast cancer. Methods Ultrasonographie changes before and after neoadjuvant chemotherapy in breast cancer were compared according to the response to neoadjuvant therapy of pathological evaluation. Results 1. The sizes of cancer became smaller or disappear mostly after neoadjuvant chemotherapy in breast cancer. 2. The response to neoadjuvant therapy operated in breast cancer were mild in 19 cases, moderate in 47 cases and severe in 12 cases by the common grading system. 3. Ultrasonographic changes before and after the neoad- juvant chemotherapy in breast cancer： All of the showing rate with surrounding hyperechoic halo increased （ P 〈 0.05 in mild cases and P 〈0.01 in moderate cases） ; All of the showing rate with spicular signs decreased, （ P 〈0.01 in moderate cases） ; All of the showing rate with lymphadenectasis decreased, （P 〈 0.01 in moderate cases and P 〈0.05 in severe cases） ; All of the blood flow in tumor detected by PDI dropped （ P 〈 0.01 in moderate cases and P 〈 0.05 in severe cases）. Conclusions To compared with uhrasonographic changes before and after neoadjuvant chemotherapy is a useful technique to evaluate response of breast cancer.